CureVac NV
(XTER:5CV)
€
2.912
-0.018 (-0.61%)
Market Cap: 667.92 Mil
Enterprise Value: 500.70 Mil
PE Ratio: 0
PB Ratio: 1.83
GF Score: 47/100 - Q4 2023 CureVac NV Earnings Call TranscriptApr 24, 2024€2.27 (-4.70%)Earnings
- Q3 2023 CureVac NV Earnings Call TranscriptNov 14, 2023€5.35 (+6.79%)Earnings
- CureVac NV at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q4 2022 CureVac NV Earnings Call TranscriptApr 25, 2023€6.95 (-5.18%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptMar 28, 2023
- CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs TranscriptJan 06, 2023
- Q3 2022 CureVac NV Earnings Call TranscriptNov 16, 2022€7.89 (+2.04%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptJun 22, 2022
- CureVac NV at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- CureVac NV at Jefferies Healthcare Conference TranscriptJun 09, 2022
- CureVac NV at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q4 2021 CureVac NV Earnings Call TranscriptApr 28, 2022€15.2 (-1.05%)Earnings
- Q3 2021 CureVac NV Earnings Call TranscriptNov 19, 2021€36.83 (+4.54%)Earnings
- CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call TranscriptOct 12, 2021
- CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call TranscriptJul 01, 2021
- CureVac NV Updates On Clinical Trial - Corporate Call TranscriptJun 17, 2021
- Q4 2020 CureVac NV Earnings Call TranscriptApr 15, 2021€89 (+3.91%)Earnings
- CureVac N.V. - Special Call TranscriptFeb 05, 2021
CureVac NV at Jefferies Healthcare Conference Transcript
Jun 09, 2022 / 01:30PM GMT
Release Date Price:
€14.86
(-6.25%)
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst
Happy to conduct a fire sided chat with the CureVac, and presenting from CureVac is Pierre, CFO and Sarah, Head of IR. So thanks for joining me today this morning.
Pierre Kemula
CureVac N.V. - MD, CFO & Member of Management Board
Thank you very much.
Sarah Fakih
CureVac N.V. - VP Corporate Communications & IR
Thank you.
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst
Okay. So before we go in -- before we go into specific questions, can you talk -- give us a kind of overview of what CureVac is trying to achieve?
Pierre Kemula
CureVac N.V. - MD, CFO & Member of Management Board
Absolutely. Good morning, everyone. It's a pleasure to be here. So I mean, we are basically an mRNA company, right, trying to, of course, express all the value of mRNA in infectious diseases. We've announced
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)